IMUNON Secures Valuable Extension to Compliance Plan
Management of IMUNON is happy to announce an extension granted by the Nasdaq Hearing Panel, offering the company more time to finalize its compliance plan. This is a significant move for IMUNON, a clinical-stage company actively engaged in the development of its innovative DNA-mediated immunotherapy technologies.
Compliance Plan Granted by Nasdaq Hearing Panel
Thanks to a comprehensive plan submitted to the Nasdaq Hearing Panel, IMUNON (Nasdaq: IMNN) can maintain its listing on the Nasdaq Stock Market. Notably, the Panel recognized the company’s successful fundraising efforts which have already bolstered its compliance with Equity Rule requirements.
Commitment to Compliance
IMUNON has displayed a strong commitment to upholding compliance by presenting an actionable strategy to the Hearing Panel. The special exception awarded allows the company additional time needed to ensure it meets both the shareholder equity requirement and the minimum bid price requirement established by Nasdaq.
Future Outlook for IMUNON
In the announcement, Stacy Lindborg, Ph.D., who serves as President and CEO of IMUNON, expressed satisfaction with the decision from the Nasdaq Hearing Panel. Dr. Lindborg stated, “We are pleased with the Nasdaq Hearing Panel’s decision, which reflects confidence in our straightforward and executable compliance plan.”
Discovering IMUNON's Innovative Therapeutic Approaches
IMUNON is at the forefront of advancing treatment options that leverage the body’s inherent abilities to generate effective and long-lasting responses to various human diseases. Their dual modality approach employs non-viral DNA technology, differentiating itself from traditional therapeutic methods.
Key Therapeutic Modalities
Among their developments are TheraPlas, focused on gene-based delivery systems for cytokines and therapeutic proteins, particularly suited for treating solid tumors, and PlaCCine, which is aimed at the gene delivery of viral antigens promising robust immunological responses.
IMNN-001 Clinical Development
IMUNON’s flagship program, IMNN-001, represents a DNA-based immunotherapy targeted at treating advanced ovarian cancer. It has undergone multiple clinical trials, aligning with the company’s dedication to leveraging innovative science for notable patient outcomes. Results are promising, as the treatment instructs the body to produce cancer-fighting molecules right where they are needed most.
Continued Research and Partnerships in Biotechnology
Additionally, IMUNON has reached a milestone with their COVID-19 booster vaccine (IMNN-101), advancing to human clinical trials. The commitment to innovative solutions is paramount as the company seeks to partner and expand their technological capabilities around plasmid DNA.
Frequently Asked Questions
What is IMUNON's focus?
IMUNON is a biotechnology company concentrating on innovative treatments using DNA-technologies to fight various diseases.
Why did Nasdaq grant an extension?
The extension was granted to allow IMUNON additional time to fulfill compliance requirements necessary for maintaining its stock market listing.
Who is the CEO of IMUNON?
Stacy Lindborg, Ph.D., serves as the President and CEO of IMUNON.
What are IMUNON's lead programs?
IMUNON’s lead clinical program is IMNN-001, targeting advanced ovarian cancer, along with a COVID-19 booster vaccine development.
How does IMUNON’s therapy work?
IMUNON’s therapies utilize the body’s own mechanisms to enhance immune responses against tumors through innovative DNA technologies.
